ANI Pharmaceuticals | ANIP - Current Liabilities


ANI Pharmaceuticals reported $283.65M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
ANI Pharmaceuticals USD 283.65M 44.14M Jun/2026
Aurora Cannabis CAD 66.93M 79M Mar/2026
Canopy Growth CAD 158.44M 60.15M Mar/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Heron Therapeutics USD 92.14M 1.63M Jun/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Omeros USD 85.5M 2.28M Jun/2025
Perrigo USD 1.05B 57.2M Jun/2026
Sun Pharmaceuticals INR 226.22B 7.93B Mar/2026
Teva Pharmaceutical Industries USD 15.65B 2.11B Jun/2026